NEIL GARRY ARTHUR
SEC insider (Form 3/4/5 filer). CIK 0001586785. Director at Celldex Therapeutics, Inc. (CLDX) and 1 other issuer. 7 reported Form 4/5 transactions since Sep 2024; latest on Jun 25, 2026. Located in HAMPTON, NJ.
Companies NEIL GARRY ARTHUR has filed insider reports for
- Celldex Therapeutics, Inc. (CLDX): Director
- Avalo Therapeutics, Inc. (AVTX): Director, Officer, Chief Executive Officer
NEIL GARRY ARTHUR
CIK: 0001586785
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (7 total)
- Jun 25, 2026CLDX
Celldex Therapeutics, Inc.
AwardDirectNon-Qualified Stock Option (right to buy)
26K shares- - May 21, 2026AVTX
Avalo Therapeutics, Inc.
AwardDirect100.2K shares- - Feb 26, 2026AVTX
Avalo Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
286K shares- - Jun 5, 2025CLDX
Celldex Therapeutics, Inc.
AwardDirectNon-Qualified Stock Option (right to buy)
16.5K shares- - Mar 28, 2025AVTX
Avalo Therapeutics, Inc.
ExerciseDirect64.9K shares- - Mar 28, 2025AVTX
Avalo Therapeutics, Inc.
Tax PaymentDirect17.8K shares at avg. $8.46$150K - Jan 28, 2025AVTX
Avalo Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
411K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 25, 2026 |  CLDX Celldex Therapeutics, Inc. | Award Non-Qualified Stock Option (right to buy) | 26,000 | - | - | Direct |
| May 21, 2026 |  AVTX Avalo Therapeutics, Inc. | Award | 100,200 | - | $0 | Direct |
| Feb 26, 2026 | AVTX Avalo Therapeutics, Inc. | Award Stock Option (Right to Buy) | 286,000 | - | - | Direct |
| Jun 5, 2025 | CLDX Celldex Therapeutics, Inc. | Award Non-Qualified Stock Option (right to buy) | 16,500 | - | - | Direct |
| Mar 28, 2025 | AVTX Avalo Therapeutics, Inc. | Exercise | 64,867 | - | - | Direct |
| Mar 28, 2025 | AVTX Avalo Therapeutics, Inc. | Tax Payment | 17,787 | $8.46 | $150,478 | Direct |
| Jan 28, 2025 | AVTX Avalo Therapeutics, Inc. | Award Stock Option (Right to Buy) | 411,000 | - | - | Direct |
1-7 of 7 transactions